Novo Nordisk Pays Up to $2.6 Billion for a Pill That Has Never Been in a Patient

Novo Nordisk signed an exclusive license agreement with China's Hengrui Pharma for HRS-1596, a once-weekly oral GLP-1/GIP dual receptor agonist, in a deal that could pay Hengrui up to $2.6 billion in upfront and milestone payments. The compound has never been approved anywhere, which makes this less an acquisition of a product than a bet on a category: the pill form of the drug class that turned Ozempic and Wegovy into household names.

The deal lands as Novo fights to defend turf it once owned outright. Its injectable CagriSema recently beat Eli Lilly's Zepbound in a head-to-head trial, a genuine win, but Lilly and a growing field of Chinese biotech partners are racing toward oral versions that could skip the needle entirely and win over patients who never wanted an injection pen in their medicine cabinet.

For a company that just spent weeks re-explaining itself through a corporate rebrand from Novo Nordisk to a leaner "Novo" identity built around "lasting health," a licensing deal like this is the substance behind the slogan: buying its way into the next fight before Eli Lilly or another rival locks up the category first.

Source: BioSpace

Kyle Duford, Founder & Editor, BRNDWIRE. More from Kyle →